Scientific consulting for rigorous, evolution-informed data analysis

I help research teams and biotech companies develop defensible analytical strategies and resistance-aware drug development approaches—before costly mistakes are made.

8+

Years analyzing evolutionary, genomic, and clinical datasets

15+

Peer-reviewed publications
in high-impact journals

2000+

Clinical bacterial isolates analyzed
with patient linkage

Some of my work

Two specialized services

Whether you're designing a clinical study or developing the next generation of antibiotics, I provide the analytical expertise to make your work rigorous, reproducible, and defensible

Early-Stage Clinical & Evolutionary Analysis BlueprintA focused engagement to clarify your analytical strategy before execution begins—preventing costly dead ends and reviewer pushback.

  • Study goal and hypothesis clarification

  • Statistical modeling strategy and validation

  • Reproducible workflow planning (R/Python)

  • Visualization and figure roadmap

  • Written summary with implementation guidance

  • Analysis implementation

Antimicrobial Resistance Strategy ConsultingEvolution-informed guidance for antibiotic development teams who want to anticipate and mitigate resistance before it becomes a crisis.

  • Resistance prediction and trajectory modeling

  • Combination therapy optimization

  • Clinical trial design with resistance endpoints

  • Regulatory strategy (FDA/EMA positioning)

  • Competitive differentiation analysis

Who this serves

My work bridges evolutionary biology, biostatistics, and clinical application—serving teams who need analytical rigor and evolutionary insight.

Research & Academic Teams, or individuals

  • Clinician-scientists integrating genomic and clinical data

  • Translational research teams navigating complex datasets

  • Academic labs preparing high-stakes grants or manuscripts

  • Early-stage biotech requiring defensible analysis strategies

  • Individuals navigating complex datasets

Pharma & Biotech Companies

  • Antibiotic developers seeking resistance mitigation strategies

  • Companies optimizing combination therapy approaches

  • Teams preparing regulatory submissions (NDA, IND)

  • Startups building investor-ready AMR narratives

Common challenges I solve

Complex biological data and evolving pathogens present persistent, costly problems. Early intervention prevents late-stage failures.

Unclear analytical questions
Study goals don't translate cleanly into testable hypotheses or appropriate models

Model mismatch
Statistical methods don't match data structure, violating assumptions

Unpredictable resistance
Drug candidates face earlier-than-expected resistance with no framework to predict trajectories

Late-stage dead ends
Analysis reveals fundamental design flaws after months of work

Regulatory uncertainty
Insufficient resistance mitigation strategies for FDA/EMA submissions

Reviewer pushback
Manuscripts or grants face criticism on analytical choices that could have been anticipated

How I work

Engagements are tailored to your specific needs but follow a structured, efficient process designed to deliver clarity quickly.

  1. Discovery: We discuss your project goals, data, constraints, and key concerns in a focused conversation

  2. Strategy Development: I develop a tailored blueprint or strategy document aligned with your objectives

  3. Review & Implementation: We review recommendations together and determine the best path forward

Expertise & background

I'm an evolutionary biologist and computational scientist with over eight years of experience analyzing large-scale genomic and clinical datasets. My research applies evolutionary principles to pressing clinical problems—from antibiotic resistance to cancer—using rigorous statistical modeling and reproducible workflows.I hold a PhD in Evolutionary Microbiology (summa cum laude) from the University of Kiel and the Max Planck Institute for Evolutionary Biology, in Germany. My work has been published in Molecular Biology and Evolution, eLife, and PLOS Biology. I was awarded the John Maynard Smith Award from the European Society for Evolutionary Biology in 2020 for outstanding early-career research.I currently work as a postdoctoral fellow at the University of Michigan, where I integrate genomic data with patient metadata to study resistance evolution in clinical settings. I have taught biostatistics at the graduate level and mentored 14+ students across undergraduate, master's, and doctoral programs.

EDUCATION
PhD, Evolutionary Microbiology
Summa Cum Laude

EXPERTISE
Biostatistics, genomics,
AMR evolution, clinical data

METHODS
R, Python, statistical modeling,
NGS analysis, reproducible workflows

Let's discuss your project

Whether you're facing a complex analytical challenge or developing resistance-aware therapies, I'd be glad to hear from you.